abrdn plc Takes Position in uniQure (NASDAQ:QURE)

abrdn plc acquired a new stake in uniQure (NASDAQ:QURE) in the 4th quarter, Holdings Channel reports. The fund acquired 400,480 shares of the biotechnology company’s stock, valued at approximately $2,711,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of QURE. BluePath Capital Management LLC purchased a new position in shares of uniQure in the 3rd quarter valued at approximately $27,000. Headlands Technologies LLC purchased a new position in shares of uniQure in the 3rd quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 222.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 4,315 shares during the last quarter. Nomura Holdings Inc. purchased a new position in shares of uniQure in the 3rd quarter valued at approximately $67,000. Finally, Laurion Capital Management LP purchased a new position in shares of uniQure in the 3rd quarter valued at approximately $73,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at uniQure

In related news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the sale, the chief operating officer now owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 27,904 shares of uniQure stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.35, for a total transaction of $177,190.40. Following the completion of the sale, the chief executive officer now directly owns 440,839 shares in the company, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,265 shares of company stock valued at $339,845. 4.05% of the stock is owned by company insiders.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $4.53 on Monday. uniQure has a 12 month low of $4.35 and a 12 month high of $22.48. The firm’s 50 day simple moving average is $5.27 and its 200-day simple moving average is $5.98. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. The business had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $3.20 million. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. As a group, sell-side analysts anticipate that uniQure will post -4.49 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on QURE. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of uniQure in a research report on Tuesday, January 16th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Friday, March 1st. HC Wainwright reduced their price target on shares of uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, March 1st. Mizuho reduced their price target on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Monday, March 4th. Finally, The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.